The Common Technical Document Explained: How Modules 1 to 5 Fit Together

Every marketing authorisation application in the EU is built on the same skeleton: the Common Technical Document (CTD). Understanding how its five modules relate to one another, and what assessors expect to find where, is the first step towards a dossier that is reviewed on its science rather than delayed by its structure.

One format, three regions

The CTD was agreed through the International Council for Harmonisation (ICH) under the M4 guideline family, so that a single, consistently organised dossier could support submissions in the EU, the United States, Japan and the many other jurisdictions that have since adopted it. In the EU, the CTD format became the legal standard for human medicines through the revised Annex I of Directive 2001/83/EC.

The CTD is usually drawn as a pyramid. Module 1 sits outside the harmonised core because it is region-specific; Modules 2 to 5 are common to all ICH regions.

What each module contains

  • Module 1 – Administrative and regional information: cover letter, application form, product information (SmPC, labelling, package leaflet), pharmacovigilance and risk management documents, and other national or EU-specific items.
  • Module 2 – Summaries: the Quality Overall Summary (2.3), the nonclinical and clinical overviews (2.4 and 2.5) and the written and tabulated summaries (2.6 and 2.7).
  • Module 3 – Quality: the drug substance (3.2.S), the drug product (3.2.P), appendices (3.2.A), regional information (3.2.R) and literature references.
  • Module 4 – Nonclinical study reports: pharmacology, pharmacokinetics and toxicology.
  • Module 5 – Clinical study reports: the tabular listing of studies, the study reports themselves and supporting literature.

Why the summaries carry so much weight

Module 2 is where assessors form their first impression. The overviews are expected to interpret the data critically, not simply restate it, and every claim should be traceable to the underlying reports in Modules 3 to 5. Inconsistencies between a summary and its source document are among the most avoidable causes of questions during assessment.

The format is evolving

ICH has released a draft revision of the quality guideline, M4Q(R2), for public consultation. It proposes extending the quality structure more explicitly to biologicals and complex products, integrating concepts from ICH Q8 to Q14 such as control strategy and established conditions, and restructuring the Quality Overall Summary. Alongside this, the move to eCTD v4.0 will change how dossier content is exchanged electronically. Applicants planning submissions over the next few years should follow both developments closely.

How PQRA helps

PQRA compiles and reviews CTD dossiers for EU and Greek submissions, from Module 1 national requirements to the scientific summaries in Module 2. We check that each module is complete, internally consistent and cross-referenced correctly before it reaches the authority.

Contact PQRA to discuss your next dossier.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *